Kyoto, Japan

Akira Ohta

This inventor holds 1 USPTO granted patent. Top assignees: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akira Ohta. Retrieved from https://idiyas.com/inventor/akira-ohta-nie711pu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akira Ohta: Innovator in Therapeutic Solutions

Introduction

Akira Ohta is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of medicine, particularly in developing therapeutic agents for rare conditions. His work has the potential to impact the lives of many individuals suffering from specific health issues.

Latest Patents

Ohta holds a patent for a therapeutic agent aimed at treating fibrodysplasia ossificans progressiva. This invention comprises at least one compound selected from a group that includes rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and their pharmaceutically acceptable salts. This innovative approach could provide new hope for patients affected by this rare condition.

Career Highlights

Throughout his career, Akira Ohta has been associated with prestigious institutions such as Kyoto University and Sumitomo Dainippon Pharma Co., Ltd. His work in these organizations has allowed him to collaborate with other experts in the field and advance his research.

Collaborations

Ohta has worked alongside notable colleagues, including Junya Toguchida and Makoto Ikeya. Their combined expertise has contributed to the development of innovative solutions in the medical field.

Conclusion

Akira Ohta's contributions to therapeutic innovations highlight the importance of research in addressing rare medical conditions. His patent for a therapeutic agent for fibrodysplasia ossificans progressiva exemplifies the potential for scientific advancements to improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…